Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Ephedrine hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
e Ephedrine Tablets
6OMFTTJOTUSVDUFE differently, take your UBCMFUTXJUIBHMBTTPG XBUFS Adults 5IFVTVBMEPTFGPSBEVMUT JTNHUISFFUJNFT EBJMZ Elderly 4NBMMFSEPTFTBSF SFRVJSFE'PSUIFFMEFSMZ the starting dose should CFIBMGUIFBEVMUEPTF Children one to five years 'PSDIJMESFOPOFUPöWF years old the usual dose JTNHUISFFUJNFTEBJMZ Children six to 12 years For children six to 12 years old the dose is VTVBMMZNHUISFFUJNFT EBJMZ
t BOYJFUZ t ESZNPVUI t GBTUPSJSSFHVMBS IFBSUCFBU UIFTFBSF NPSFMJLFMZUPPDDVSJG ZPVBSFFMEFSMZ t USFNCMJOH t IFBEBDIFT t IJHICMPPEQSFTTVSF t QPPSDJSDVMBUJPOJOZPVS fingers and toes t IFBSUBUUBDL UIJTJTB WFSZSBSFTJEFFòFDU Additional side effects in children In children ephedrine NBZDBVTFCFEXFUUJOH sleeplessness or ESPXTJOFTT If you take Ephedrine Tablets for a long time *GZPVIBWFCFFOUBLJOH &QIFESJOF5BCMFUTGPSB MPOHUJNFZPVNBZ CFDPNFEFQFOEFOUPO UIFN
Ephedrine Tablets are not recommended for children under one year Reporting of side effects of age. *GZPVHFUBOZTJEF If you take more effects, talk to your Ephedrine Tablets than EPDUPS QIBSNBDJTUPS you should OVSTF5IJTJODMVEFTBOZ *GZPVBDDJEFOUBMMZUBLF QPTTJCMFTJEFFòFDUTOPU UPPNBOZUBCMFUTDPOUBDU MJTUFEJOUIJTMFBøFU:PV ZPVSEPDUPS QIBSNBDJTU can also report side or nearest hospital FòFDUTEJSFDUMZWJBUIF DBTVBMUZEFQBSUNFOU :FMMPX$BSE4DIFNF 5BLFUIJTMFBøFUBOEBOZ XFCTJUF SFNBJOJOHUBCMFUTXJUI XXXNISBHPWVLZFMMP ZPVUPTIPXUIFEPDUPS XDBSEPSTFBSDIGPSUIF PSQIBSNBDJTU .)3":FMMPX$BSEJOUIF 4ZNQUPNTPGBO (PPHMF1MBZPS"QQMF PWFSEPTFJODMVEFCFJOH "QQ4UPSF TJDLPSGFFMJOHTJDL IJHI #ZSFQPSUJOHTJEFFòFDUT CMPPEQSFTTVSF GFWFS ZPVDBOIFMQQSPWJEF SBQJEIFBSUCFBU NPSFJOGPSNBUJPOPOUIF restlessness, difficulty TBGFUZPGUIJTNFEJDJOF CSFBUIJOHBOE DPOWVMTJPOT Hallucinations and
JODMVEJOHUIPTFZPVNBZ Ephedrine Tablets IBWFCPVHIUZPVSTFMG XJUIPVUBQSFTDSJQUJPO :PVSEPDUPSXJMMEFDJEF 1MFBTFDIFDLXJUIZPVS UIFEPTFXIJDIJTCFTUGPS EPDUPSJGZPVBSFUBLJOH ZPV"MXBZTUBLFUIJT BOZPGUIFGPMMPXJOH PS NFEJDJOFFYBDUMZBT BOZPUIFSNFEJDBUJPO doctor has told you and t UIFPQIZMMJOF BTJNJMBS BMTPGPMMPXBOZTQFDJBM drug used to treat JOTUSVDUJPOTPSXBSOJOHT TFWFSFBTUINBBOE XIJDINBZBQQFBSPOUIF other conditions DBVTJOHPCTUSVDUJPOPG MBCFMXIJDIUIF QIBSNBDJTUIBTQVUPO UIFBJSXBZTJOZPVS UIFQBDLBHF$IFDLXJUI lungs your doctor or t Tricyclic QIBSNBDJTUJGZPVBSFOPU antidepressants, such TVSF
include: t GFFMJOHTJDL t SFTUMFTTOFTT t JOTPNOJB EJóDVMUZJO TMFFQJOH
Keep this medicine out of the sight and reach of children. %POPUUBLFUIJT NFEJDJOFBGUFSUIFFYQJSZ EBUFXIJDIJTTUBUFEPO UIFMBCFM5IFFYQJSZEBUF SFGFSTUPUIFMBTUEBZPG UIBUNPOUI %POPUUBLFUIJT NFEJDJOFJGZPVOPUJDF TJHOTPGEFUFSJPSBUJPO TVDIBTEJTDPMPSBUJPO %POPUTUPSFBCPWF¡$ Store in the original container or package in PSEFSUPQSPUFDUGSPN MJHIUBOENPJTUVSF %POPUUISPXBXBZ NFEJDJOFTWJB XBTUFXBUFSPSIPVTFIPME XBTUF"TLZPVS QIBSNBDJTUIPXUPUISPX BXBZNFEJDJOFTZPVOP MPOHFSVTF5IFTF NFBTVSFTXJMMQSPUFDUUIF FOWJSPONFOU
EFMVTJPOTNBZBMTPPDDVS Ephedrine Tablets If you forget to take Ephedrine Tablets *GZPVGPSHFUUPUBLFB dose, take another as TPPOBTZPVSFNFNCFS*G JUJTBMNPTUUJNFGPSZPVS next dose, then do not UBLFBNJTTFEEPTFBUBMM %POPUUBLFBEPVCMF EPTFUPNBLFVQGPSB GPSHPUUFOUBCMFU If you stop taking Ephedrine Tablets :PVTIPVMEDPOUJOVFUP UBLF&QIFESJOF5BCMFUT GPSBTMPOHBTZPVSEPDUPS UFMMTZPVUP%POPUTUPQ UBLJOHUIFNFEJDJOF XJUIPVUUBMLJOHUPZPVS EPDUPSöSTU *GZPVIBWFBOZGVSUIFS RVFTUJPOTPOUIFVTFPG UIJTNFEJDJOF BTLZPVS EPDUPSPSQIBSNBDJTU 4. Possible side effects -JLFBMMNFEJDJOFT UIJT NFEJDJOFDBODBVTFTJEF effects, although not FWFSZCPEZHFUTUIFN
What Ephedrine Tablets contain 5IFBDUJWFJOHSFEJFOUJO
&QIFESJOF5BCMFUTJT FQIFESJOFIZESPDIMPSJEF 5IFUBCMFUTBSFBWBJMBCMF JOUXPTUSFOHUIT NH
BOENH5IFPUIFS JOHSFEJFOUTJO&QIFESJOF 5BCMFUTBSFMBDUPTF NBJ[F starch, acacia TQSBZESJFE TUFBSJDBDJE BOENBHOFTJVNTUFBSBUF What Ephedrine Tablets look like and contents of the pack &QIFESJOF)ZESPDIMPSJEF NH5BCMFUTBSFXIJUF DJSDVMBSUBCMFUTNBSLFE &POPOFGBDFBOE$1 POUIFSFWFSTF &QIFESJOF)ZESPDIMPSJEF NH5BCMFUTBSFXIJUF DJSDVMBSUBCMFUTNBSLFE &POPOFGBDFBOE$1 POUIFSFWFSTF &QIFESJOF5BCMFUTBSF BWBJMBCMFJO polypropylene or QPMZFUIZMFOF QMBTUJD DPOUBJOFSTPG PS UBCMFUTPSCMJTUFS QBDLTPG PSUBCMFUT /PUBMMQBDLTJ[FTNBZCF NBSLFUFE Marketing Authorisation Holder 8PDLIBSEU6,-UE "TI3PBE/PSUI 8SFYIBN –6' 6, Manufacturer $11IBSNBDFVUJDBMT-UE "TI3PBE/PSUI 8SFYIBN –6' 6, Other formats To listen to or request a DPQZPGUIJTMFBøFUJO #SBJMMF MBSHFQSJOUPS BVEJPQMFBTFDBMM GSFFPG charge: 0800 198 5000 (UK only) 1MFBTFCFSFBEZUPHJWF UIFGPMMPXJOH JOGPSNBUJPO Product name
Reference number
&QIFESJOF Hydrochloride NH5BCMFUT &QIFESJOF )ZESPDIMPSJEF NH5BCMFUT 5IJTJTBTFSWJDFQSPWJEFE CZUIF3PZBM/BUJPOBM *OTUJUVUFPG#MJOE1FPQMF 5IJTMFBøFUXBTMBTU SFWJTFEJO
Ephedrine Hydrochloride 30mg Tablets comes as tablet containing 30mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Ephedrine Hydrochloride 30mg Tablets is ephedrine hydrochloride.
This leaflet reproduces the patient information leaflet approved for Ephedrine Hydrochloride 30mg Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Ephedrine tablets are indicated for the treatment or prevention of attacks of bronchospasm in asthma.
Posology
Adults
15 – 60mg three times daily
Children
under 1 year
1 – 5 years
6 – 12 years
not recommended
15mg three times daily
30mg three times daily
Elderly
Dosage should be substantially reduced. Initial therapy should be 50% of adult dose.
Method of administration
For oral use.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Ischaemic heart disease
• Hypertension
• Thyrotoxicosis
• Prostatic hypertrophy
Ephedrine has positive inotropic and chronotropic effects on the heart and its use should be avoided in patients with ischaemic heart disease.
Ephedrine increases blood pressure in humans. Over the counter acquisition of sympathomimetics should always be considered in hypertensive patients whose blood pressure control has suddenly deteriorated.
Patients with hyperthyroidism may be susceptible to the effects of ephedrine. Ephedrine may precipitate acute urinary retention in patients with prostatic hypertrophy.
Ephedrine should be given with care to patients with hyperthyroidism, diabetes mellitus, angle-closure glaucoma and renal impairment.
Ephedrine has potentially life threatening effects in its acute cardiovascular and central stimulant effects.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Other adrenoceptor stimulants: Concurrent use of ephedrine with theophylline may result in increased nausea, nervousness, and insomnia.
Anaesthetics: There may be an increased risk of arrhythmias when used with volatile liquid anaesthetics.
Antidepressants: Ephedrine should not be given to patients who are being treated with monoamine oxidase inhibitors as they may cause hypertensive crisis with marked headache, severe hypertension and subarachnoid haemorrhage. Noradrenaline is displaced by ephedrine with the release of large amounts of catecholamine. The interaction may occur up to two weeks after stopping MAOI therapy. There may be an increased risk of arrhythmias when ephedrine is used with tricyclic antidepressants.
Antihypertensives: Loss of blood pressure control has been detected in hypertensive patients undergoing concurrent therapy with ephedrine and adrenergic neurone blocking drugs and may also occur with other antihypertensives.
Antimigraine drugs: Enhanced vasoconstriction and pressor effects with ergotamine or methysergide; concurrent use of ergotamine not recommended (risk of gangrene).
Cardiac glycosides: Increased risk of arrhythmias in patients receiving ephedrine and cardiac glycosides.
Corticosteroids: Ephedrine has been shown to increase the clearance and prolong the half-life of dexamethasone in asthmatic patients.
Oxytocin: Increased risk of vasoconstrictor or pressor effects in patients receiving oxytocin and ephedrine
Urinary acidifiers/alkalinisers: Effects of ephedrine may be reduced by acidification and increased by alkalinization of the urine.
Pregnancy
The use of ephedrine in pregnancy should be avoided as ephedrine crossed the placenta and this has been associated with an increase in foetal heart rate and beat to beat variability.
Breast-feeding
Ephedrine is excreted in breast milk and therefore its use during lactation should be avoided. Irritability and disturbed sleep patterns have been reported in breast fed infants.
Ephedrine tablets have no influence on the ability to drive and use machines.
The most common side-effects of ephedrine are tachycardia, anxiety, nausea, restlessness and insomnia. Tremor, dry mouth, impaired circulation to the extremities, hypertension, headache and cardiac arrhythmias may occur. Tolerance with dependence has been reported with prolonged administration.
Myocardial infarction has occurred very rarely in patients taking ephedrine or pseudoephedrine.
Paediatric Population
Ephedrine may act as stimulant in children with nocturnal enuresis and cause sleeplessness. It may have sedative effects in some children.
Elderly
The elderly are more sensitive to the cardiovascular effects of ephedrine.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for the MHRA Yellow Card in the Google Play or Apple App Store.
a) Symptoms
The symptoms of overdose are normally seen as nausea, vomiting, hypertension, fever, palpitations, tachycardia, restlessness, respiratory depression and convulsions. Paranoid psychosis, delusions and hallucinations may also follow ephedrine overdosage.
b) Treatment
In severe overdosage, the stomach should be emptied by emesis and lavage. Management is by supportive symptomatic therapy.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Ephedrine Hydrochloride 30mg Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.